Abstract
Melanoma therapy is moving away from combinatorial approaches and towards newer targeted strategies. With the identification of mutations in various RAS pathway genes, there are now tremendous opportunities to bring inhibitors of RAS signalling to the clinical arena.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Cell Transformation, Neoplastic / genetics*
-
Humans
-
MAP Kinase Signaling System / genetics
-
Melanoma / drug therapy
-
Melanoma / genetics*
-
Mutation
-
Phosphatidylinositol 3-Kinases / genetics
-
Skin Neoplasms / drug therapy
-
Skin Neoplasms / genetics*
-
ras Proteins / genetics
Substances
-
Antineoplastic Agents
-
Phosphatidylinositol 3-Kinases
-
ras Proteins